PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
60 hedge funds and large institutions have $84.3M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 9 closing their positions.
Holders
60
Holders Change
+10
Holders Change %
+20%
% of All Funds
1.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
18
Reduced
14
Closed
9
Calls
$89K
Puts
$79K
Net Calls
+$10K
Net Calls Change
+$10K
Top Buyers
1 |
1
BlackRock
New York
|
$4.98M |
2 |
2
Ameriprise
Minneapolis,
Minnesota
|
$406K |
3 |
3
Morgan Stanley
New York
|
$743K |
4 |
4
Millennium Management
New York
|
$734K |
5 |
5
AllianceBernstein
Nashville,
Tennessee
|
$200K |